InsiderStreet Equity Research

Produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation for any investor. Do not rely on it for any investment decision.

Last Close

$255.56

2026-10-16

Market Cap

$615.9B

Volume

6.4M

52-Wk High

$281.07

52-Wk Low

$184.66

Trailing PE

38.7

P/S

6.20

Gross Margin

68.8%

Net Margin

16.2%

ROE

20%

ROIC

15%

Piotroski

6/9

Altman Z

5.3

1-Yr Return

+33.9%

5-Yr Return

+135.0%

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

SectorHealthcareIndustryDrug Manufacturers - GeneralExchangeNYSEMarket Cap$615.9BEmployees138,200 (SEC-filed)CEOJoaquin DuatoIPO1962-01-02CountryUS

One Johnson & Johnson Plaza, New Brunswick, NJ 08933 · Tel 732 524 0400 · jnj.com

INSIDERSTREET SCORE64 / 100Street mean $286.50 (14 analysts, last qtr) — their number, not ours

INSIDER CONSENSUS SIGNALROUTINE SELLING — LOW SIGNAL$68M sold / 6 mo, zero open-market buys

INSIDERSTREET
SCORE64of 100

Score Breakdown

Profitability	85/100
Growth	42/100
Momentum	67/100
Quality	84/100
Earnings Quality	74/100
Balance Sheet	69/100
Value	42/100
Risk (safety)	100/100
Overall	64.2/100

Each component is a diagnostic reading on its own 0-100 scale. The overall score is computed separately from the underlying financials and is not the average of the rows above — components are not equally weighted and three of them (Momentum, Value, Risk) are derived partly from price rather than from the business.

Peer Comparison — IS Score

Symbol	IS Score
ABBV	67
MRK	49
LLY	78
NVS	65
AZN	71
AMGN	67
JNJ	64

IS Score Trend — quarterly

14 quarters, 23 Q1 to 26 Q2. Peak 71 in 24 Q2, latest 64 — -7 since. Fell in 2 of the last 4 quarters. Dashed line marks 40 on the 0-100 scale.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

1 Year vs S&P 500 · JNJ +33.9% · S&P 500 +15.9% · spread +18.0pp

7 Years vs S&P 500 · JNJ +135.0% · S&P 500 +189.9% · spread -54.8pp

Both charts indexed to 100 at the start of their window and drawn on a single shared scale, so the gap to the benchmark is the gap you see. Adjusted closes throughout.

BUSINESS QUALITY64 / 100IS Score 64.2 / 100 · -6.7 from peak of 71

Fundamental factor model, quarterly. Measures how the business is doing - not where the price is going.

PRICE STRUCTUREBEARISHTechnical Score 24 / 100 · Power -51 · 4 of 22 indicator votes bullish

Vote share across trend, momentum, volume, volatility and pattern families. Describes where the price is, not where it is going.

These two disagree — business quality 64, price structure 24 out of 100, so the business reads better than the price does. We publish the disagreement rather than resolving it: they answer different questions, and the gap between them is information, not an error.

Trigger	Where it stands now	What it would mean
IS Score reaches 75 and holds two consecutive quarters	now 64.2	would move us up one band
IS Score stops falling - one quarter higher than the prior	last four: 69 → 68 → 61 → 64	the direction matters more than the level
Technical vote share back above 50%	now 18%	price structure no longer broken
Institutional holder count rises two quarters running	peak 4,706 → now 4,706	fewer institutions willing to hold is our clearest warning

We publish these so the view can be shown to be wrong. If none of them move and our reading does, we owe you an explanation.

This page is InsiderStreet's own reading, produced from the data in the rest of this document. It is not a price target and not investment advice. Analyst consensus and street price targets appear later under their own heading and are the street's numbers, not ours.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Site Convergence Score3 of 4top 4% of 29,420 symbols

Sources Aligned— of 3independent disclosures

Congress (180d)8 buys2026-09-25

Insider Buys (180d)0none disclosed

ETF Funds (30d)1827 up / 1628 downnet +199 funds

Institutions Added (13F)46managers opening or increasing

Congressional and insider figures are disclosed purchases in the trailing 180 days; ETF figures are COUNTS OF FUNDS whose holding changed in 30 days, not dollars. Coincidence of separate disclosures, not coordination. An absent source means nothing qualifying was disclosed in its window.

Institutions holding — 12 quarters

Peak 4,706 · latest 4,706 (+0 from peak).

Quarter	Holders	13F shares	Value	Reported own%
2026 Q2	4,706	1817.8M	$450.8B	74.5%
2026 Q1	4,660	1775.9M	$424.2B	72.8%
2025 Q4	4,552	1778.5M	$361.3B	72.9%
2025 Q3	4,200	1731.6M	$316.7B	71.0%
2025 Q2	4,101	1759.7M	$264.6B	72.1%
2025 Q1	4,166	1746.0M	$285.4B	71.5%
2024 Q4	4,119	1734.5M	$246.4B	71.1%
2024 Q3	3,896	1721.6M	$271.3B	70.5%
2024 Q2	3,818	1706.5M	$243.3B	69.9%
2024 Q1	3,866	1686.5M	$260.1B	69.1%
2023 Q4	3,884	1673.7M	$257.8B	68.6%
2023 Q3	3,690	1666.9M	$255.7B	68.3%

How to read ownership above 100%. A 13F reports the positions a manager has investment discretion over, and where two or more managers share discretion over the same block, each one reports it. Summed across filers, the total can therefore exceed the shares actually outstanding without anything being wrong. We publish the figure as filed rather than netting it down, and flag separately any quarter where the arithmetic is not merely high but impossible.

Insider	Role	Date	Type	Shares	Value	Post-Txn Owned
Pinto Daniel E	director	2026-09-08	A-Award	113	—	2,445
Woods Eugene A.	director	2026-09-08	A-Award	136	—	6,579
Hewson Marillyn A	director	2026-09-08	A-Award	181	—	16,049
Schmid Timothy	EVP, WW Chair, MedTech	2026-09-02	EXERCISE	11,070	$1.46M	36,517
Schmid Timothy	EVP, WW Chair, MedTech	2026-09-02	SELL	22,527	$6.19M	25,447
Schmid Timothy	EVP, WW Chair, MedTech	2026-09-02	EXERCISE	22,527	$3.41M	47,974
Schmid Timothy	EVP, WW Chair, MedTech	2026-09-02	EXERCISE	11,070	$1.46M	0
Schmid Timothy	EVP, WW Chair, MedTech	2026-09-02	EXERCISE	22,527	$3.41M	0

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

6-mo decomposition (Form 4)	Txns	Shares	Value	Signal weight
S — Open-market sales	11	262,345	$68.2M	Counted
M — Exercises (paired A/D)	10	243,616	$26.7M	None — mechanics
F — Tax withholding	1	11,002	$2.5M	None — compensation
P — Open-market purchases	0	0	$0	Counted — none occurred

Monthly Net Insider Flow (000 shares)

Net of acquisitions minus dispositions, all Form 4 types.

Signal Summary

SignalRoutine Selling — Low Signal

Open-Market Sells$68.2M11 txns / 6 mo

Open-Market Buys$0.0M0 txns / 6 mo

ClusterNone active3+ insiders / 21 days

Filed	Filer	Shares registered	Est. proceeds
2026-09-02	Schmid Timothy	33,597	$9.2M
2026-08-17	Taubert Jennifer L	15,000	$4.0M
2026-08-13	Duato Joaquin	123,291	$32.2M
2026-08-06	Forminard Elizabeth	15,918	$4.1M
Trailing 12 mo	20 filings	703,210	$168M

Filed	Form	Reporting person	% of class	Shares
2026-05-01	SCHEDULE 13G	Vanguard Capital Management	7.49%	180.6M sh
2026-03-26	SCHEDULE 13G/A	The Vanguard Group	—	exit/reporting change
2026-02-05	SCHEDULE 13G/A	The Vanguard Group	10.10%	243.5M sh

Member	Chamber	Trade	Size band	Traded	Disclosed
Ro Khanna	House	BUY	$1,001 - $15,000	2026-09-25	2026-10-09
Lloyd Doggett	House	BUY	$1,001 - $15,000	2026-09-08	2026-10-06
Ro Khanna	House	BUY	$15,001 - $50,000	2026-09-04	2026-10-09
John Boozman	Senate	SELL	$1,001 - $15,000	2026-08-20	2026-09-11
John Boozman	Senate	SELL	$1,001 - $15,000	2026-08-20	2026-09-11
John Boozman	Senate	SELL	$1,001 - $15,000	2026-08-20	2026-09-10

House 12-Mo64 trades22 purchases

Senate 12-Mo6 trades1 purchases

CoverageSTOCK Act filings30-45 day disclosure lag

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

13F Filers (last complete Q)4,660

13F Shares1.78B72.8% of shares out

New / Closed303 / 120positions, QoQ

Increased / Reduced1,716 / 2,166positions, QoQ

Put/Call (13F)1.08option positions

Free Float99.8%2.41B sh

2.8 · Largest Reporting 13F Managers

Manager	Shares	Value
Ninety One Uk Ltd	6.5M	$1.7B
Assenagon Asset Management S.A.	3.0M	$792M
Wealth Enhancement Advisory Servic	2.0M	$464M
Pinestone Asset Management Inc.	1.6M	$433M
Td Waterhouse Canada Inc.	1.2M	$319M
Fjarde Ap-Fonden /Fourth Swedish N	1.1M	$293M

EDGAR 13F holdings as of 2026-09-30; filer values normalized to dollars.

2.9 · Top ETF & Fund Ownership

Fund	Weight	Position
VITSX	0.9%	$20.3B
VTI	0.9%	$20.3B
VTSAX	0.9%	$20.3B
VSMPX	0.9%	$20.3B
VFIAX	1.0%	$16.8B
VFFSX	1.0%	$16.8B

13F Filers Holding JNJ — quarterly

Institutional Put/Call — quarterly

Daily short-sale volume as % of volume reported in FINRA's short-sale file — a flow measure, not short interest; dashed = 50-day average.

Latest Session27.6%2026-10-15

20-Day Avg45.0%50-day 49.6%

TrendFalling20d vs 50d

By Market CenterQ: 27% · N: 47% · B: 22%latest session

Weekly Notional ($B)

Where JNJ Trades in the Dark

ATS Venue (4-wk)	Shares	Avg trade
Incr Intelligent Cross Llc	7.0M	42 sh
Ubsa Ubs Ats	6.0M	48 sh
Ebxl Level Ats	4.2M	31 sh
Sgmt Sigma X2	3.5M	48 sh
Mlix Instinct X	3.2M	73 sh
Pure Purestream	3.0M	55 sh

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Where a dollar of Johnson & Johnson revenue goes. All values FY2025 filings, live.

Region	Revenue	Share
UNITED STATES	$53.8B	57%
Europe	$21.5B	23%
Asia-Pacific, Africa	$14.0B	15%
Western Hemisphere, excluding U.S.	$4.9B	5%

JNJ (live moat model)Peer median: ABBV · MRK · LLY · NVS · AZN

Component scores from the live moat model. Peer median illustrative.

Moat score 62/100 — Narrow; primary source Efficient Scale.

3.8 · Employees (SEC filings)

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Officer	Title
Joaquin Duato	Chief Executive Officer & Chairman
Joseph J. Wolk	Executive Vice President & Chief Financial Officer
John C. Reed	Executive Vice President of Innovative Medicine and R&D
Timothy Schmid	Executive Vice President & Worldwide Chairman of MedTech

Revenue ($B)

EPS ($) — GAAP diluted actual, street-basis estimate

Actual bars are GAAP diluted EPS from the filed income statement; the lighter forward bars are street-basis consensus. The two are different measures and are not comparable quarter to quarter.

Quarterly EPS — Actual vs. Consensus

Beats (>2%)2 of 6recent quarters

Avg Surprise+1.7%

Next Report2027-01-20

Income Quality1.13OCF ÷ net income

Beat Rate—%0 of 0 quarters

Current Streak0longest 0

Avg EPS Surprise—%median —%

Surprise Trend—last 4 vs prior 4

Period	EPS est.	EPS actual	EPS surprise	Rev est. ($M)	Rev actual ($M)	Rev surprise

Announcement dates to . Consensus as it stood at each report. Revenue surprise shown where both estimate and actual are filed. A beat record is history, not a forecast.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Profit Margins (%)

Revenue by Segment — Stacked

Live segmentation data.

YoY Growth Heatmap — Income Lines

YoY growth	FY21	FY22	FY23	FY24	FY25
Revenue	-4.7%	+1.6%	+6.5%	+4.3%	+6.0%
Gross profit	+2.2%	+0.1%	+5.8%	+4.7%	+11.7%
Operating income	+6.1%	+0.3%	+11.4%	-5.4%	+15.6%
Net income	+41.9%	-14.1%	+95.9%	-60.0%	+90.6%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

$B · FY ends	FY21	FY22	FY23	FY24	FY25
Revenue	78.7	80.0	85.2	88.8	94.2
Cost of revenue	23.4	24.6	26.6	27.5	25.6
Gross profit	55.3	55.4	58.6	61.4	68.6
R&D expense	14.3	14.1	15.1	17.2	14.7
SG&A expense	20.1	20.2	20.1	22.0	23.7
Operating income	20.9	21.0	23.4	22.1	25.6
EBITDA	26.8	26.6	23.3	24.8	39.9
D&A	7.4	7.0	7.5	7.3	7.3
Pretax income	19.2	19.4	15.1	16.7	32.6
Income tax	1.4	3.0	1.7	2.6	5.8
Net income	20.9	17.9	35.2	14.1	26.8
Diluted EPS ($)	7.81	6.73	13.72	5.79	11.03
Diluted shares (M)	2,674	2,664	2,560	2,429	2,429

Operating CF$25B

CapEx$5B

Free cash flow$20B

SBC$1B

Buybacks$6B

Net cash change$-4B

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet — Full

$B	FY22	FY23	FY24	FY25
Cash & equivalents	12.9	21.9	24.1	19.7
ST investments	9.4	1.1	0.4	0.4
Receivables (net)	16.9	14.9	18.9	17.2
Total current assets	55.3	53.5	55.9	55.6
PP&E (net)	18.0	19.9	20.5	23.2
Goodwill + intangibles	74.5	70.7	81.8	99.2
Total assets	187.4	167.6	180.1	199.2
Accounts payable	9.9	9.6	10.3	12.0
Short-term debt	12.8	3.5	6.0	8.5
Deferred revenue	0.0	0.0	0.0	0.0
Total current liabilities	55.8	46.3	50.3	54.1
Long-term debt	26.9	25.9	30.7	39.4
Total liabilities	110.6	98.8	108.6	117.7
Shareholders' equity	76.8	68.8	71.5	81.5

Cash Flow Statement — Full

$B	FY22	FY23	FY24	FY25
Net income	17.9	13.3	14.1	26.8
D&A	7.0	7.5	7.3	7.5
Stock-based compensation	1.1	1.2	1.2	1.4
Working capital change	(4.0)	2.5	1.8	(12.7)
Operating cash flow	21.2	22.8	24.3	24.5
Capital expenditures	(4.0)	(4.5)	(4.4)	(4.8)
Investing cash flow	(12.4)	0.9	(18.6)	(23.6)
Buybacks	(6.0)	(5.1)	(2.4)	(6.0)
Dividends paid	(11.7)	(11.8)	(11.8)	(12.4)
Debt issuance / (repay)	7.5	(2.7)	10.1	9.6
Financing cash flow	(8.9)	(15.8)	(3.1)	(5.5)
Free cash flow	17.2	18.2	19.8	19.7

Balance Sheet Structure ($B)

Cash Generation vs Capex ($B)

Left: what the balance sheet is made of — the gap between the assets bar and the liabilities bar is book equity. Right: whether the capex bar is covered by the operating-cash bar; where it is not, the difference was funded externally and free cash flow goes negative.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
PROFITABILITY
ROE	30.4%	23.8%	48.3%	20.1%	35.0%	20%
ROA	11.7%	9.7%	19.8%	8.1%	14.1%	8.0%
ROIC	29.5%	19.9%	27.5%	22.2%	19.4%	14.7%
Gross margin	70.3%	69.3%	68.8%	69.1%	72.8%	68.8%
Operating margin	26.6%	26.3%	27.5%	24.9%	27.2%	25.7%
Net margin	26.5%	22.4%	41.3%	15.8%	28.5%	16.2%
EBITDA margin	34.0%	33.3%	27.4%	27.9%	42.4%	31.0%
FCF margin	21.1%	18.9%	21.4%	20.3%	20.9%	—
VALUATION
P/E	19.46	23.94	10.19	24.21	18.89	38.7
P/B	5.49	5.59	5.21	4.76	6.21	7.4
P/S	4.33	4.71	4.21	3.83	5.38	6.20
P/FCF	20.56	25.00	19.64	18.86	25.71	32.9
EV/EBITDA	13.46	15.78	15.64	14.23	13.09	20.9
EV/Revenue	4.36	4.90	4.28	3.97	5.67	6.5
Earnings yield	5.1%	4.2%	9.8%	4.1%	5.3%	2.57%
FCF yield	4.9%	4.0%	5.1%	5.3%	3.9%	3.04%

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
LEVERAGE & SOLVENCY
Current ratio	1.35	0.99	1.16	1.11	1.03	1.09
Quick ratio	1.12	0.81	0.91	0.86	0.77	0.81
Debt / equity	0.46	0.52	0.43	0.51	0.59	0.58
Debt / assets	18.5%	21.2%	17.5%	20.3%	24.1%	24.4%
Net debt / EBITDA	0.07	0.61	0.27	0.49	0.68	0.93
Interest coverage	125.46	77.36	20.51	23.10	44.79	—

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
EFFICIENCY
Asset turnover	0.53	0.49	0.48	0.51	0.50	0.49
Receivables turnover	6.50	6.22	5.89	5.98	5.88	5.2
DSO (days)	56	59	62	61	62	70
DPO (days)	126	130	134	132	135	109
Cash conversion cycle	51	57	75	86	88	140
GROWTH (YoY)
Revenue growth	13.6%	-2.8%	-6.6%	4.3%	6.0%	—
Net income growth	41.9%	-14.1%	95.9%	-60.0%	90.6%	—
EPS growth	41.8%	-13.9%	114.7%	-59.9%	89.6%	—
FCF growth	-2.1%	-13.0%	6.2%	-1.0%	9.1%	—
PER SHARE ($)
EPS (diluted, TTM)	7.82	6.73	14.46	5.80	10.99	6.58
Book value / share	27.72	28.83	28.29	29.45	33.43	34.72
Revenue / share	35.12	34.22	35.03	36.60	38.62	40.59
FCF / share	7.40	6.45	7.51	7.44	8.08	7.64
Cash / share	11.84	8.36	9.43	10.10	8.24	8.48
SHAREHOLDER RETURN & SCORES
Buyback yield	0.9%	1.4%	1.4%	0.7%	0.8%	0.99%
Altman Z-Score	4.24	4.15	4.33	3.94	4.80	5.3
Piotroski F-Score	8	4	7	6	4	6/9
Beneish M-Score	-2.25	-2.62	-2.29	-2.49	-2.44	-2.49

Model	Score	Zone	Note
Piotroski F-Score	6 / 9	Middling
Altman Z-Score	5.3	Safe (>2.99)	Safe
Income quality	1.13	Cash-backed	OCF ÷ net income
Beneish M-Score	-2.49	Non-manipulator	vs −2.22 threshold

DuPont Decomposition (TTM)	Value
Tax burden	0.83
Interest burden	0.97
Operating margin	26.5%
Asset turnover	0.50×
Financial leverage	2.41×
= ROE	26%

Growth Quality (live)	Value
Revenue stability	0.39
Earnings stability	0.11
Earnings persistence	0.97
Revenue CAGR 3y	4.4%
EPS CAGR 3y	20.1%
FCF CAGR 3y	8.7%

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Buyback Yield0.99%

Dividend Yield2.07%

Total Shareholder Return2.63%cash yield

SBC / Revenue1.4%dilution pressure

Company	Mkt cap	P/E	ROE	Net margin	Rev growth	Piotroski	1-yr ret
ABBV	$504.4B	80.4	-206%	21.3%	+10.4%	7/9	+25.8%
MRK	$360.1B	115.8	7%	-8.0%	+4.5%	4/9	+75.4%
LLY	$1,183.3B	42.1	102%	30.9%	+49.6%	9/9	+53.6%
NVS	$286.3B	22.9	31%	22.7%	+0.8%	5/9	+15.1%
AZN	$256.5B	24.7	22%	16.3%	+8.6%	9/9	—
AMGN	$233.8B	26.7	91%	23.6%	+9.2%	8/9	—
GILD	$193.7B	-60.1	-21%	—	+5.5%	5/9	—
PFE	$168.6B	39.1	5%	-1.6%	-0.2%	7/9	—

1-yr returns computed from adjusted price history; peers without a tracked series show —.

Buy

40 Analysts

Str Sell (0)Sell (3)Hold (16)Buy (21)Str Buy (0)

Mean Target (qtr)$286.5014 targets

Target vs. Price+12.1%last-quarter mean

Next Report2027-01-20street $2.93

Consensus estimates	Revenue mean	High / Low	EPS mean	High / Low	# EPS est.
FY2026	$101.23B	$101.50B / $100.85B	$11.16	$11.25 / $11.09	10
FY2026	$98.94B	$99.97B / $98.18B	$11.48	$11.72 / $11.34	13
FY2026	$100.31B	$101.01B / $98.32B	$11.57	$11.67 / $11.48	13

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Street Price Target — Trajectory

Window	Avg Target	vs. Price	# Targets
Last Month	$277.75	+8.7%	8
Last Quarter	$286.50	+12.1%	14
Last Year	$259.33	+1.5%	55
All Time	$219.85	-14.0%	110

Rolling mean of published targets vs. last close $255.56. Aggregated from StreetInsider, Benzinga, Pulse 2.0.

Third-Party Composite Rating

C-

DCF

4/5

ROE

1/5

ROA

1/5

Debt/Eq

1/5

P/E

1/5

P/B

1/5

Independent quant composite as of 2026-10-16; components scored 1–5 (5 best). Shown for contrast with the InsiderStreet Score — methodologies differ.

JNJ +33.9% vs S&P 500 +15.9% — spread +18.0pp

Sector — XLV +24.2%

Peer Set — indexed to 100

All series indexed to 100 at the start of the window, adjusted closes.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Candlesticks with SMA 20/50 overlay, Bollinger (20,2σ) band, volume, and Wilder RSI(14) — computed from live daily OHLCV.

Moving Average	Value	Distance	% Distance	Signal
SMA 20	$261.39	-5.83	-2.23%	Below
SMA 50	$264.94	-9.38	-3.54%	Below
SMA 200	$243.80	+11.76	+4.82%	Above
EMA 9	$256.36	-0.80	-0.31%	Below
EMA 21	$259.90	-4.34	-1.67%	Below
EMA 50	$261.19	-5.63	-2.16%	Below
EMA 200	$241.54	+14.02	+5.80%	Above

Series and readings from the nightly technical-indicator history — identical data to the site's ribbon chart. Supertrend segments colored by direction.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

TECHNICAL VERDICTBEARISHPower Score -514 of 22 indicator votes bullish

Family Scores (site weights)

Trend 30%22

Momentum 25%20

Volume 20%19

Volatility 10%0

Patterns 15%62

This Week18% bullishof 11 price-based votes

4 Weeks Ago73%-55 pts since

12 Weeks Ago82%-64 pts since

ReadDeterioratingweek-over-week trajectory

Price vs SMA 20$261.39

Price vs SMA 50$264.94

Price vs SMA 200$243.80

EMA 9/21 Cross256.4/259.9

SMA 50/200Golden

ADX DirectionADX 16

Supertrend$268

Parabolic SAR$263

SMA Slope-0.720

RSI43.8

Stochastic K/D33/29

StochRSI K/D50/42

Williams %R-61

CCI-60

TSI vs Signal-16.7

CMO-12.4

ROC-0.18%

OBV SignalDistrib

Chaikin MF-0.120

MFI32

Force Index-16M

Elder Ray Bull-2.35

RSI (14)30 oversold · 70 overbought

Stochastic %Kvs %D 29

Money Flowvolume-weighted RSI

ADXtrend strength · <20 weak

Williams %Rinverted scale

Level	Value	Level	Value
Pivot / R1 / R2	$256.12 / $259.61 / $265.95	S1 / S2	$249.78 / $246.29
Bollinger (20,2)	$246.98 – $275.81	Squeeze	Off
52-wk range	$183.49 – $281.07	Off 52-wk high	-9.1%
ATR (14)	$6.20 (2.4%)	Historical vol	27.4%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

-0.0%Jan50%

+0.0%Feb55%

+1.2%Mar62%

+2.1%Apr65%

-0.3%May60%

+1.1%Jun55%

+2.1%Jul65%

+0.3%Aug55%

+0.3%Sep55%

+1.0%Oct65%

+1.8%Nov60%

+0.4%Dec55%

Sample: 20 years — treat short histories as suggestive, not statistical.

Computed from live weekly prices	JNJ	S&P 500
Weekly volatility (σ, 1y)	2.84%	1.83%
Best / worst week (1y)	+6.2% / -6.2%	—
Max drawdown (5y, monthly)	-19.2%	—
1-week VaR (95%)	-4.2%	—
Beta (5y)	0.23	1.00

JNJ EQUITY WEATHER (LIVE)RAINY · -35

Trend-28

Momentum-16

Volume-51

Volatility-60

Breadth-30

MARKET REGIME (2026-10-16)NEUTRAL

VIX19.99Normal

Dow TheoryConfirmed Bearish

SPY / QQQ TSI7.2 / 4.7trend strength

Sector Strength46/100breadth average

Average sentiment of 1,081 stories, weekly buckets, −1 to +1.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Overall-34.7-25.2 vs industry

Trend-28.3-24.2 vs industry

Momentum-15.9-25.8 vs industry

Volume-51.1-67.7 vs industry

Reading	JNJ	Drug Manufacturers - General n=150	Healthcare n=5,272	All US symbols n=70,435
Overall	-34.7	-9.5	-24.0	-20.5
Trend	-28.3	-4.1	-25.6	-21.3
Momentum	-15.9	+9.9	-28.5	-15.8
Volume	-51.1	+16.6	-25.0	-3.8

Trend, momentum and volume are computed per company. Volatility and breadth are market-regime values shared by every symbol in the universe, so they are reported once under Market Regime rather than compared here - a company cannot differ from its sector on a constant.

Executive	Total comp	Structure
J. Duato Chairman/CEO	$32.8M	59% equity+incentive
J. Wolk EVP, CFO	$14.4M	56% equity+incentive
J. Taubert EVP, WWC Innovative Medicine	$14.0M	58% equity+incentive
J. Reed EVP, Innovative Medicine, R&D	$12.2M	65% equity+incentive
T. Schmid EVP, WWC, MedTech	$9.3M	53% equity+incentive

Pillar (live disclosure scores)	Score
Environmental	83
Social	70
Governance	73
Composite ESG	75

Composite ESG Trend

Filed	8-K contents	Items
2026-10-13	Earnings Release; Exhibits	2.02,9.01
2026-08-04	Officer/Director Change; Exhibits	5.02,9.01
2026-07-29	Regulation FD; Exhibits	7.01,9.01
2026-07-28	Regulation FD; Exhibits	7.01,9.01
2026-07-15	Earnings Release; Exhibits	2.02,9.01
2026-04-28	Shareholder Vote; Exhibits	5.07,9.01
2026-04-14	Earnings Release; Other Events; Exhibits	2.02,8.01,9.01
2026-01-21	Results of Operations and Financial Condition; Financial Statements an	2.02,9.01

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Methodology. Every figure originates in InsiderStreet's production data layer and is computed deterministically by the same engines that power insiderstreet.ai. This factsheet contains no model-written text. Sections without underlying data are omitted rather than estimated.

DISCLOSURES. This document is produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation tailored to any person. Data is sourced as of the dates shown and may no longer be current. InsiderStreet.ai is not a registered investment adviser or broker-dealer. Investing involves risk, including loss of principal. Past performance does not guarantee future results. Do not make any investment decision based on this document. © 2026 InsiderStreet.ai — all rights reserved. Redistribution prohibited.

Data domain	Source	Coverage for this report
Price & volume	market_db.historical_prices	52 rows
Fundamentals	income_statements_annual	6 rows · 2020 to 2025
Reported vs consensus	fact/earnings_calendar	24 rows · 2021-01-26 to 2026-10-13
Analyst estimates	dim/forward_estimates	3 rows · 2026-12-28 to 2026-12-31
Institutional ownership (13F)	holdings_db.institutional_ownership_summary	124 rows · 1987 to 2026
Insider transactions (Form 4)	edgar/form4	12 rows · 2026-09-01 to 2026-09-08
Proposed sales (Form 144)	edgar/form144	1 record
Beneficial ownership (13D/G)	edgar/13dg	3 rows · 2026-02-05 to 2026-05-01
Short-sale volume (FINRA)	edgar/short_volume_daily	60 rows · 2026-07-23 to 2026-10-15
Dark pool (ATS, tier 1)	edgar/darkpool_weekly	12 rows · 2026-06-15 to 2026-08-31
ETF & fund holding	etf_holdings_changelog (30d)	1 record
Peer set	stock_peers_dynamic	8 rows
Industry medians	industry_medians	1 record
Congressional trades	congress_db (House + Senate)	1 record
ESG	fact/esg_disclosures	1 record

Method. Every figure in this factsheet is looked up from a named field computed in code. It contains no model-written text.

Not covered. Short interest as a percent of float and days-to-cover are not in this data set — the short-sale figures above are FINRA volume, a flow, and cannot support squeeze or covering analysis. Options positioning and intraday data are also absent. 13F ownership is filed 45 days after quarter end and congressional trades are disclosed on a lag, so both describe a past position, not a current one.

Johnson & Johnson (JNJ)

Score Breakdown

Peer Comparison — IS Score

IS Score Trend — quarterly

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)

Institutions holding — 12 quarters

Johnson & Johnson (JNJ)

Monthly Net Insider Flow (000 shares)

Signal Summary

Johnson & Johnson (JNJ)

2.8 · Largest Reporting 13F Managers

2.9 · Top ETF & Fund Ownership

13F Filers Holding JNJ — quarterly

Institutional Put/Call — quarterly

Where JNJ Trades in the Dark

Johnson & Johnson (JNJ)

3.8 · Employees (SEC filings)

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)

Balance Sheet — Full

Cash Flow Statement — Full

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)

Street Price Target — Trajectory

Third-Party Composite Rating

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)

Family Scores (site weights)

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)